Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Phase 3 Recruiting
264 enrolled
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Phase 3 Recruiting
12 enrolled
THYME
Phase 2 Recruiting
15 enrolled
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Phase 2/3 Recruiting
12 enrolled
MG-ARCADIA
Recruiting
50 enrolled
EPIC
Phase 3 Recruiting
115 enrolled
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Phase 4 Recruiting
40 enrolled
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
Recruiting
450 enrolled
SYNAPSE-MG
Phase 2 Recruiting
84 enrolled
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Phase 3 Recruiting
180 enrolled
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Phase 3 Recruiting
231 enrolled
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Phase 3 Recruiting
199 enrolled 11 charts
ziMyG
Phase 2/3 Recruiting
8 enrolled
roMyG
Phase 2/3 Recruiting
12 enrolled
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Phase 1 Recruiting
32 enrolled
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Phase 1 Recruiting
30 enrolled
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Phase 3 Recruiting
146 enrolled
RELIEVE
Phase 3 Recruiting
180 enrolled
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Recruiting
500 enrolled
ADAPT Jr
Phase 2/3 Recruiting
12 enrolled
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Recruiting
70 enrolled
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Recruiting
680 enrolled
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
Recruiting
279 enrolled
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Phase 3 Recruiting
100 enrolled
Synergy-MG
Phase 1/2 Recruiting
96 enrolled
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Phase 1 Recruiting
120 enrolled
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Phase 2 Recruiting
70 enrolled
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Phase 1/2 Recruiting
15 enrolled
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Recruiting
40 enrolled
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Phase 2/3 Recruiting
66 enrolled
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Phase 3 Recruiting
120 enrolled
ADAPT Jr SC
Phase 2/3 Recruiting
12 enrolled
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Phase 1 Recruiting
44 enrolled
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
Phase 1 Recruiting
50 enrolled
VRMG
Recruiting
600 enrolled
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Phase 1/2 Recruiting
54 enrolled
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Recruiting
1,000 enrolled
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Phase 2/3 Recruiting
104 enrolled
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting
20,000 enrolled